PRMT6 Antibody (YA5188)

PRMT6 (protein arginine methyltransferase 6) is a type I protein arginine methyltransferase that catalyzes mono- and asymmetric dimethylation of arginine residues and functions predominantly as a nuclear epigenetic regulator of gene expression^[1][8]. Mechanistically, PRMT6 deposits the repressive histone mark H3R2me2a, and this modification antagonizes H3K4 trimethylation, thereby influencing chromatin organization and transcriptional programs controlling cellular proliferation and differentiation^[2][3]. Through regulation of H3R2 methylation at target promoters, PRMT6 modulates expression of cell-cycle regulators including p21 and p27, linking arginine methylation to G2 checkpoint control and cell-cycle progression in experimental models^[4]. Beyond cell-cycle regulation, PRMT6 participates in broader epigenetic and DNA methylation networks through H3R2me2a-dependent effects on chromatin-associated regulatory machinery^[8][5]. In disease contexts, dysregulated PRMT6 expression has been associated with multiple cancers, where it influences cell growth, migration, invasion, apoptosis, drug resistance, and tumor progression pathways^[6][7]. Compared with related PRMT family members, PRMT6 is distinguished by its strong association with H3R2 asymmetric dimethylation and the resulting antagonistic relationship with H3K4me3-dependent transcriptional activation^[2][3]. For experimental applications, increasing efforts have focused on the development of selective and non-selective PRMT6 modulators, including isoform-selective inhibitors, dual-target inhibitors, covalent inhibitors, and targeted degradation strategies, providing useful chemical tools for mechanistic studies and therapeutic target validation in cancer research^[7].